Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1

Launched by ANN & ROBERT H LURIE CHILDREN'S HOSPITAL OF CHICAGO · Feb 3, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on studying a condition called Neurofibromatosis type 1 (NF1), which can lead to the development of tumors, specifically a type known as plexiform neurofibromas. The researchers want to find specific markers in the blood that could help identify these tumors more easily, especially in children. Currently, checking for these tumors often requires extensive imaging, which can be challenging. In this study, the team will use advanced techniques like whole-body MRI and mass spectrometry to gather information about these tumor markers in patients who already have NF1 and known tumors.

To participate in this trial, you need to have a confirmed diagnosis of NF1. Unfortunately, individuals who don't meet the diagnostic criteria, those with a specific form of NF1 called mosaic NF1, pregnant participants, or those who can't provide consent will not be eligible. If you take part in the study, you can expect to undergo imaging and blood tests to help researchers learn more about the tumor markers associated with NF1. The ultimate goal is to improve understanding and management of this condition for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Individuals with known diagnosis of neurofibromatosis type 1 (NF1)
• Exclusion Criteria:
• • 1. Patient does not meet NF1 diagnostic criteria
• • 2. Mosaic NF1 individuals
• • 3. Pregnant at Screening
• • 4. Patients who do not have the ability/capacity to undergo the informed consent process OR whose parent/legal guardian is unable to undergo the informed consent process.